Crisaborole
Common brands: Eucrisa, Dupixent, Allergy Relief, Allergy Nasal, Envarsus Xr
Top reporter: Pfizer Laboratories Div Pfizer Inc
Phosphodiesterase 4 Inhibitor [EPC]Interleukin-4 Receptor alpha Antagonist [EPC]Corticosteroid [EPC]Calcineurin Inhibitor Immunosuppressant [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]
9,465
Total Reports
2,852
Serious Reports
24
Death Reports
30
Reported Reactions
Death Report Ratio: Low (0.25%)
Patient Demographics
Reported Adverse Reactions (30)
Side effects reported in FDA adverse event reports for Crisaborole.
| # | Reaction | Reports | % of Total |
|---|---|---|---|
| 1 | DRUG INEFFECTIVE | 1,971 | |
| 2 | APPLICATION SITE PAIN | 1,416 | |
| 3 | BURNING SENSATION | 985 | |
| 4 | OFF LABEL USE | 753 | |
| 5 | CONDITION AGGRAVATED | 704 | |
| 6 | PRURITUS | 633 | |
| 7 | RASH | 606 | |
| 8 | PAIN | 526 | |
| 9 | ECZEMA | 451 | |
| 10 | DERMATITIS ATOPIC | 433 | |
| 11 | ERYTHEMA | 370 | |
| 12 | PRODUCT USE IN UNAPPROVED INDICATION | 334 | |
| 13 | DRUG HYPERSENSITIVITY | 260 | |
| 14 | DRY SKIN | 256 | |
| 15 | DRUG INEFFECTIVE FOR UNAPPROVED INDICATION | 243 | |
| 16 | APPLICATION SITE ERYTHEMA | 234 | |
| 17 | SKIN BURNING SENSATION | 233 | |
| 18 | THERAPEUTIC PRODUCT EFFECT INCOMPLETE | 219 | |
| 19 | PRODUCT USE ISSUE | 203 | |
| 20 | SKIN EXFOLIATION | 180 | |
| 21 | URTICARIA | 149 | |
| 22 | DRUG EFFECTIVE FOR UNAPPROVED INDICATION | 146 | |
| 23 | HYPERSENSITIVITY | 143 | |
| 24 | APPLICATION SITE PRURITUS | 139 | |
| 25 | SKIN DISORDER | 139 | |
| 26 | TREATMENT FAILURE | 123 | |
| 27 | PRODUCT DOSE OMISSION ISSUE | 119 | |
| 28 | EYE IRRITATION | 108 | |
| 29 | DISCOMFORT | 107 | |
| 30 | DERMATITIS | 106 |
Important Disclaimer
FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.